Categories
Latest Industry Intelligence
Lu Rahman takes look at some of the latest imaging innovation available and how it [...]
To understand Switzerland’s continued success in the biotech sector and gain personal insights, Lu Rahman [...]
Steve Gardner, CEO PrecisionLife, examines the lack of return on investment for pharmaceutical R&D and the huge pockets of unmet medical need in common chronic disorders. Over the last decade [...]
By Naheed Kurji, Co-founder and Executive of the Alliance for Artificial Intelligence in Healthcare (AAIH), CEO of Cyclica; and Andreas Windemuth, Ph.D, Chief Science Officer of Cyclica Over the past [...]
Lu Rahman takes look at some of the latest imaging innovation available and how it can benefit drug target identification and drug discovery research. Imaging is an important element within [...]
Lu Rahman looks at the role precision medicine is playing in how we approach the patient and the way we treat disease. We hear increasingly about the shift away from [...]
In the aftermath of Covid-19, ambitious strategies for digital transformation are seen as a wise investment as life sciences organisations upgrade their capacities for managing clinical trials and the scientific [...]
As the world’s largest generic producer how far advanced is India’s drug discovery push and where does it stand on the global stage? Lu Rahman explores. India has become a [...]
A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare diseases potentially the biggest beneficiaries of positive Covid-19 legacies [...]
Lu Rahman looks at the rise of proteomics, its growing role in the quest for new treatments and some of the work being carried out in this field. Due to the [...]
Advancements in technology, and in particular, developments in artificial intelligence (AI) are revolutionising the way that we live our lives. Up to now, we have used it to help us [...]
The Personalized Medicine Coalition The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized [...]
Collaborative Research Leads To New Understanding Of Biomarkers By Dr Max Ryadnov and Professor Jason Crain A new collaborative research paper sheds light on the way antibodies distinguish between different [...]
Guidelines & Recommendations For Analyzing and Interpreting GPCR Second Messenger Data Sponsored by CisBio The question of choosing which methods to use for analyte quantification (signal vs concentration determination, parameters, [...]
Menu ≡ ╳ 
